Vima Therapeutics, a clinical-stage biotechnology company focused on oral therapies for movement disorders, launched today with a $60M Series A financing led by Atlas Venture, with participation from Access Industries and Canaan. With a patient-focused approach, and highly experienced leadership team, Vima is advancing VIM0423, a potential first-in-class oral therapy for dystonia that targets the underlying cause in the central nervous system.